Axsome Therapeutics (AXSM) Stock Forecast & Price Target
Score
Axsome Therapeutics, Inc. price target
| AXSM | |
|---|---|
| Low | $238.00 |
| Average | $279.25 |
| High | $380.00 |
| Upside vs current price | +97.1% |
The average target of $279.25 is +97.1% versus the current AXSM price of $141.69.
Axsome Therapeutics, Inc. analyst ratings
| Rating | Analysts |
|---|---|
| Strong buy | 3 |
| Buy | 18 |
| Hold | 1 |
| Sell | 0 |
| Strong sell | 0 |
| Consensus | Buy |
22 analysts cover AXSM.
Axsome Therapeutics, Inc. EPS and revenue estimates
The estimate table for the Axsome Therapeutics, Inc. keeps 2026 EPS $-2.56, 2027 EPS $3.52, and years with fewer than three analysts are not filled in.
| Fiscal year | EPS estimate | Revenue estimate |
|---|---|---|
| 2026 | $-2.56 | $954.09M |
| 2027 | $3.52 | $1.46B |
Is Axsome Therapeutics, Inc. a buy or sell?
Of the 22 analysts covering Axsome Therapeutics, Inc., 21 rate it a buy (3 strong buy and 18 buy), 1 rates it a hold, and 0 rate it a sell (0 sell and 0 strong sell).
The AXSM consensus label is Buy, beside 21 buy-side ratings and 0 sell-side ratings.
The average target of $279.25 implies +97.1% versus the current price of $141.69.
the Axsome Therapeutics, Inc. closes with 21 buy-side ratings and 0 on the sell side. The headcount is Buy.
Reading the Axsome Therapeutics, Inc. forecast
Analysts are far apart on AXSM. The published low is $238.00, the average is $279.25, and the high is $380.00.
From today's $141.69 print, the AXSM average target is +97.1% away.
Most of the AXSM coverage agrees: 21 of 22 analysts are on the buy side, 1 is at hold, and 0 are on the sell side, and the published consensus is Buy.
AXSM targets have eased: $242.33 in the last month against $260.14 over the last quarter.
Coverage of AXSM is broad at 22 analysts, and the average is a crowd rather than a single desk.
Axsome Therapeutics, Inc. forecast questions
What is the AXSM price target?
The published range for AXSM is $238.00 to $380.00, with an average of $279.25. That average is +97.1% versus the current price of $141.69.
Is Axsome Therapeutics, Inc. a buy or sell?
Of the 22 analysts covering Axsome Therapeutics, Inc., 21 rate it a buy, 1 rates it a hold, and 0 rate it a sell. The consensus is Buy, which for AXSM is 21 on the buy side, 1 at hold, and 0 on the sell side.
What is the EPS estimate for Axsome Therapeutics, Inc.?
Analyst EPS estimates for Axsome Therapeutics, Inc.: 2026 $-2.56, 2027 $3.52.
What is the revenue estimate for Axsome Therapeutics, Inc.?
Analyst revenue estimates for Axsome Therapeutics, Inc.: 2026 $954.09M, 2027 $1.46B.
How many analysts cover AXSM?
22 analysts cover AXSM. Their consensus on AXSM is Buy, across those 22.